Evidence map›Paper›PMID 40214673›Full record

ArticleWiener klinische Wochenschrift2025

High lymphocyte count and bleeding risk in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors.

Ivan Krečak, Bruna Kvinta, Marina Paladin, Aron Grubešić, Marija Stanić Damić, Neven Franjić, Josipa Budimir, Josipa Antonija Bačić, Davor Galušić, Zinaida Perić and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ivan KrečakDepartment of Internal Medicine, General Hospital of Šibenik-Knin County, Stjepana Radića 83, 22000, Šibenik, Croatia. krecak.ivan@gmail.com.
Bruna KvintaCity Pharmacies Zagreb, Zagreb, Croatia.
Marina PaladinPharmacy Department, University Hospital Center Rijeka, Rijeka, Croatia.
Aron GrubešićFaculty of Medicine, University of Rijeka, Rijeka, Croatia.
Marija Stanić DamićFaculty of Medicine, University of Rijeka, Rijeka, Croatia.
Neven FranjićFaculty of Medicine, University of Rijeka, Rijeka, Croatia.
Josipa BudimirDepartment of Internal Medicine, General Hospital of Šibenik-Knin County, Stjepana Radića 83, 22000, Šibenik, Croatia.
Josipa Antonija BačićDepartment of Internal Medicine, General Hospital of Šibenik-Knin County, Stjepana Radića 83, 22000, Šibenik, Croatia.
Davor GalušićDivision of Hematology, University Hospital Center Split, Split, Croatia.
Zinaida PerićFaculty of Medicine, University of Rijeka, Rijeka, Croatia.
Marko SkelinFaculty of Medicine, University of Rijeka, Rijeka, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bruton's tyrosine kinase inhibitors (BTKi) are being increasingly used to treat patients with chronic lymphocytic leukemia (CLL). Pathological bleeding is a well-known side effect of BTKi but identifying its predictors remains a challenge. This retrospective multicenter study analyzed whether baseline absolute lymphocyte count (ALC) may be associated with bleeding risk in CLL patients treated with BTKi. Time to bleeding (TTB) was the primary outcome of interest. A total of 108 CLL patients treated with BTKi (ibrutinib, n = 86, acalabrutinib, n = 22) were included. The median age was 70 years (range 41-88 years) and 48 (44.4%) were female. The median follow-up time was 32 months (range 1-108 months) and 17 (15.7%) bleeding events occurred during this time. Receiver operating curve analysis set the optimal cut-off value of the ALC at > 77.4 × 10

Indexed as

Agammaglobulinaemia Tyrosine KinaseBenzamidesHemorrhageLeukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsPyrazolesAdenineAdultAgedAged, 80 and overComorbidityFemaleHumansLymphocyte CountMaleMiddle AgedacalabrutinibAdenineAgammaglobulinaemia Tyrosine KinaseBenzamidesibrutinibPiperidinesProtein Kinase InhibitorsPyrazinesPyrazolesPyrimidinesTyrosine Kinase InhibitorsBleedingChronic lymphocytic leukemiaRiskTreatment

Identifiers

PMID40214673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.